In vitro and in vivo effects of a long-acting anti-influenza agent CS-8958 (laninamivir octanoate, Inavir®) against pandemic (H1N1) 2009 influenza viruses

Japanese Journal of Antibiotics

Volumn 63, Issue 5, 2010, Pages 337-346

  Kubo, Shuku ^a   Kakuta, Masayo ^a   Yamashita, Makoto ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CS 8958; INAVIR; LANINAMIVIR OCTANOATE; LONG ACTING DRUG; SIALIDASE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BINDING; ENZYME INHIBITION; IC 50; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; JAPAN; MOUSE; NONHUMAN; SINGLE DRUG DOSE; VIRUS CULTURE; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS LOAD; VIRUS REPLICATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIVIRAL AGENTS; CELLS, CULTURED; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DOGS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; JAPAN; LUNG; MICE; MICE, INBRED BALB C; NEURAMINIDASE; PANDEMICS; VIRAL LOAD; VIRUS REPLICATION; ZANAMIVIR;

EID: 78649456920     PISSN: 03682781     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. FIORE, A. E.; D. K. SHAY, P. HABER, et al.: Prevention and control of influenza. Recommendations of the advisory committee on immunization practices (ACIP). MMWR Recommend. Rep. 56 (RR-6): 1-54, 2007
2. WRIGHT, P. F. & R. G. WEBSTER: Orthomyxoviruses, pp. 1534-1579. In D. M. KNIPE, P. M. HOWLEY, D. E. GRIFFIN, et al. (ed.), Fields virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, PA. 2001
3. Novel swine-origin influenza A (H1N1) virus investigation team: Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 360: 2605-2615, 2009
4. http://idsc.nih.go.jp/idwr/douko/2010d/10douko.html#chumoku1
5. HAY, A. J.; A. J. WOLSTENHOLME, J. J. SKEHEL, et al.: The molecular basis of the specific anti-influenza action of amantadine. EMBO J. 4: 3021-3024, 1985
6. BRIGHT, R. A.; D. K. SHAY, B. SHU, et al.: Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295: 891-894, 2006
7. BRIGHT, R. A.; D. SHAY, J. BRESEE, et al.: High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents - United States, 2005-06 influenza season. MMWR Morb. Mortal. Wkly. Rep. 55: 44-46, 2006
8. GUBAREVA, L.; M. OKOMO-ADHIAMBO, V. DEYDE, et al.: Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb. Mortal. Wkly. Rep. 58: 433-435, 2009
9. KISO, M.; Y. MITAMURA, K. SAKAI-TAGAWA, et al.: Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364: 759-765, 2004
10. HATAKEYAMA, S.; N. SUGAYA, M. ITO, et al.: Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 297: 1435-1442, 2007
11. LACKENBY, A.; O. HUNGNES, S. G. DUDMAN, et al.: Emergence of resistance to oseltamivir among influenza A (H1N1) viruses in Europe. Euro. Surveill. 13: 1-2, 2008
12. Infectious Agents Surveillance Report 29: 334-339, 2008
13. Infectious Agents Surveillance Report 30: 287-297, 2009
14. http://www.who.int/csr/disease/influenza/H1N1webupdate20090318%20ed-ns. pdf
15. http://www.cdc.gov/flu/weekly/weeklyarchives2008-2009/weekly15.htm
16. LE, Q. M.; M. KISO, K. SOMEYA, et al.: Avian flu: isolation of drug-resistant H5N1 virus. Nature 437: 1108, 2005
17. http://www.who.int/csr/disease/swineflu/laboratory18-06-2010/en/index. html
18. Infectious Agents Surveillance Report 31: 173-178, 2010
19. NGUYEN, T.; T. G. SHEU, V. P. MISHIN, et al.: Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob. Agents Chemother. 54: 3671-3677, 2010
20. YAMASHITA, M.; T. TOMOZAWA, M. KAKUTA, et al.: CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob. Agents Chemother. 53: 186-192, 2009
21. KISO, M.; S. KUBO, M. OZAWA, et al.: Efficacy of the new neuraminidase H5N1 influenza viruses. PLoS Pathog. 6: e1000786, 2010
22. KUBO, S.; T. TOMOZAWA, M. KAKUTA, et al.: Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Antimicrob. Agents Chemother. 54: 1256-1264, 2010
23. ITOH, Y.; K. SHINYA, M. KISO, et al.: In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460: 1021-1025, 2009
24. KOYAMA, K.; M. TAKAHASHI, M. OITATE, et al.: CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long retention profile in the mouse respiratory tract. Antimicrob. Agents Chemother. 53: 4845-4851, 2009
25. SUGAYA, N. & Y. OHASHI: Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob. Agents Chemother. 54: 2575-2582, 2010
26. WATANABE, A.; S-C. CHANG, M. J. KIM, et al.: Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, non-inferiority clinical trial. Clin. Infect. Dis. (in press)
27. KUBO, T.; M. AGOH, L. Q. MAI, et al.: Development of a reverse transcription-loop-mediated isothermal amplification assay for detection of pandemic (H1N1) 2009 virus as a novel molecular method for diagnosis of pandemic influenza in resource-limited settings. J. Clin. Microbiol. 48: 728-735, 2010
28. PALESE, P. & M. YAMASHITA: Evolutionary lineage and molecular epidemiology of influenza A, B, and C viruses. pp. 119-129, In E. KURASTAK, R. G. MARUSYK, F. A. MURPHY, et al. (ed), Applied Virology Research. Plenum Publishing Corporation. New York, NY. 1990